Morepen Laboratories Limited (NSE:MOREPENLAB)

Market Cap	33.41B
Revenue (ttm)	18.30B
Net Income (ttm)	1.18B
Shares Out	n/a
EPS (ttm)	2.20
PE Ratio	28.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	487,625
Average Volume	9,106,924
Open	61.38
Previous Close	60.96
Day's Range	60.52 - 61.40
52-Week Range	42.00 - 100.90
Beta	0.96
RSI	59.54
Earnings Date	May 5, 2025

About Morepen Laboratories

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermome...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 2,152
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MOREPENLAB

Financial Performance

In 2023, Morepen Laboratories's revenue was 17.02 billion, an increase of 19.68% compared to the previous year's 14.22 billion. Earnings were 961.60 million, an increase of 148.63%.